Search Results for: interactions

Drug-Drug Interactions Between DAAs and ARVs

HCV Guideline Committee, August 2020 Use of DAAs concurrently with ART may lead to clinically relevant drug interactions. Table 38, below, lists the potential drug-drug interactions between DAA regimens and select ART regimens and Box 3, below, lists other resources on drug-drug interactions in patients with HIV/HCV coinfection. Tenofovir is a nucleoside reverse transcriptase inhibitor … Continue reading “Drug-Drug Interactions Between DAAs and ARVs”

Classifications and Mechanisms of Drug-Drug Interactions

Reviewed and updated: John Faragon, PharmD, BCPS, AAHIVP; July 2021 Writing Group: Joseph P. McGowan, MD, FACP, FIDSA; Steven M. Fine, MD, PhD; Samuel T. Merrick, MD; Asa E. Radix, MD, MPH, PhD, FACP, AAHIVS; Rona M. Vail, MD; Christopher J. Hoffmann, MD, MPH; Charles J. Gonzalez, MD Committee: Medical Care Criteria Committee Original author: Joshua R. Sawyer, PharmD, … Continue reading “Classifications and Mechanisms of Drug-Drug Interactions”

Identifying Drug-Drug Interactions

Reviewed and updated: John Faragon, PharmD, BCPS, AAHIVP; July 2021 Writing Group: Joseph P. McGowan, MD, FACP, FIDSA; Steven M. Fine, MD, PhD; Samuel T. Merrick, MD; Asa E. Radix, MD, MPH, PhD, FACP, AAHIVS; Rona M. Vail, MD; Christopher J. Hoffmann, MD, MPH; Charles J. Gonzalez, MD Committee: Medical Care Criteria Committee Original author:  Joshua R. Sawyer, PharmD, … Continue reading “Identifying Drug-Drug Interactions”

Drug-Drug Interactions

HCV Guideline Committee, updated August 2020 The charts contained in this section are meant to provide guidance on significant interactions between DAAs and common primary care medications. While these guidelines can be helpful, they are not a substitute for sound clinical judgment and practice. In some cases, the medications listed below are contraindicated in the U.S. Food … Continue reading “Drug-Drug Interactions”

Drug-Drug Interactions by Antiretroviral (ARV) Class

Reviewed and updated: John Faragon, PharmD, BCPS, AAHIVP; July 2021 Writing Group: Joseph P. McGowan, MD, FACP, FIDSA; Steven M. Fine, MD, PhD; Samuel T. Merrick, MD; Asa E. Radix, MD, MPH, PhD, FACP, AAHIVS; Rona M. Vail, MD; Christopher J. Hoffmann, MD, MPH; Charles J. Gonzalez, MD Committee: Medical Care Criteria Committee Original author: Joshua R. Sawyer, PharmD, … Continue reading “Drug-Drug Interactions by Antiretroviral (ARV) Class”

Drug-Drug Interactions by Common Medication Class

Reviewed and updated: John Faragon, PharmD, BCPS, AAHIVP; July 2021 Writing Group: Joseph P. McGowan, MD, FACP, FIDSA; Steven M. Fine, MD, PhD; Samuel T. Merrick, MD; Asa E. Radix, MD, MPH, PhD, FACP, AAHIVS; Rona M. Vail, MD; Christopher J. Hoffmann, MD, MPH; Charles J. Gonzalez, MD Committee: Medical Care Criteria Committee Original author: Joshua R. Sawyer, PharmD, … Continue reading “Drug-Drug Interactions by Common Medication Class”

Guideline Updates, Development, and Ratings

Guideline Information Developer and Funding Source New York State Department of Health AIDS Institute (NYSDOH AI) Intended Users NYS clinicians who are initiating therapy in nonpregnant, ART-naive adults with HIV Development See Guideline Development and Recommendation Ratings Scheme, below. Updates October 8, 2021; MCCC with Antonio E. Urbina, MD New recommendation regarding 2-drug initial ART: With the exception … Continue reading “Guideline Updates, Development, and Ratings”

Treatment of HIV-2

Lead author: Sanjiv S. Shah, MD, MPH, AAHIVS, with the Medical Care Criteria Committee; October 2021 RECOMMENDATIONS Table 1: Preferred ART Regimens for Initial Treatment of Nonpregnant Adults With HIV-2 [a] (listed alphabetically; for specific details, see drug package inserts; for full recommendations on initiating ART in patients with HIV, see the NYSDOH AI guideline Selecting … Continue reading “Treatment of HIV-2”